Catalytic degradation of p-nitrophenol by magnetically recoverable Fe3O4 as a persulfate activator under microwave irradiation.
In this study, Fe3O4 and microwave (MW) were combined to activate persulfate (PS) for the removal of organic matter, resulting in the enhanced degradation of p-nitrophenol (PNP) in solution. During the preparation of Fe3O4, the effect of sodium acetate was examined, and the results showed that the concentration of sodium acetate had little effect on the catalytic activity of the Fe3O4/PS/MW system but did have an effect on the Fe3O4 yield. In addition, with regards to the representative environmental factors, the degradation experiment showed that humic acid and the co-existing anions of chloride, sulfate, nitrate, and phosphate had little effects on p-nitrophenol removal; however, carbonate had a negative effect. In addition, the Fe3O4/PS/MW system performed well in the initial pH range of 3.0-9.0. According to the quenching experiment and electron paramagnetic resonance (EPR) detection, sulfate radicals and a minority of hydroxyl radicals play dominant roles in the degradation process. In addition, the role of Fe3O4 was confirmed to take part in the degradation process by X-ray photoelectron spectroscopy (XPS) analysis. Because of the good performance observed in the water matrices of tap water and the Songhua River, these results demonstrate the potential application of the Fe3O4/PS/MW system for wastewater treatment. PMID: 31726600 [PubMed - in process]
Antioxidants&Redox Signaling, Ahead of Print.
Publication date: Available online 10 December 2019Source: Seminars in Ultrasound, CT and MRIAuthor(s): Satheesh Krishna, Ashley Leckie, Ania Kielar, Robert Hartman, Ashish KhandelwalAbstractCystic renal masses are common incidental findings on cross-sectional imaging. Accurate characterisation of cystic renal masses is essential to guide management. Renal mass protocol comprises of a good quality non-contrast, corticomedullary and nephrographic phases with each phase providing complementary information for diagnosis. Attenuation measurements in different phases are central to the ‘golden-rules’ in renal mass i...
This article reviews the risks and benefits of GBCA administration.
Publication date: Available online 10 December 2019Source: European Journal of RadiologyAuthor(s): Arun Jose, Akhil Kher, Robert E. O’Donnell, Jean M. ElwingAbstractPurposeTargeted treatment for pulmonary arterial hypertension (PAH), diagnosed via right heart catheterization (RHC), has been shown to improve morbidity and mortality. Identifying characteristics that predict clinical worsening has been challenging. We sought to evaluate the role of cardiac Magnetic Resonance Imaging (CMR) as a predictor of clinical worsening in a cohort of treatment-naïve pulmonary hypertension (PH) patients.MethodsWe performed a r...
Events: Conference Call Bayer 2030 Sustainable Development ObjectivesLive today at approx. 2:00 p.m. CET (1:00 p.m. UTC): Investor Conference Call: Bayer 2030 Sustainable Development ObjectivesLink to websiteAll changes
Bayer to significantly step-up its sustainability efforts2030 target to be carbon neutral in own operations / Ambitious 2030 objectives for access to health and nutrition in low- and middle-income countries and underserved communities / Measurable sustainability targets to be incorporated into management compensationmehr ...
to the article “Attachment Disorders,” by Gail Hornor, published in the September/October 2019 issue of the Journal (Journal of Pediatric Health Care, 33, 612–622).
This article presents a case report that illustrates how evasive the diagnosis of pericardial effusion can be. The early symptoms of pericardial effusion resemble common viral conditions that can easily be overlooked. Subtle presenting symptoms and the importance of urgent multidisciplinary collaboration and emergent referral for the child with pericarditis are summarized.
This article provides an overview of CALMs, followed by a summary of several conditions associated with CALMs ranging from the most common (neurofibromatosis type 1) to rare, ring chromosome syndromes.